Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2M fell 47.8% year over year, ahead of the -60.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at -22.0% a year.

Context

  • Stock-based compensation amounted to 98.1% of revenue in FY2025, down 206.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -47.8% holds above the trailing-twelve-month pace of -60.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2M+8.5% QoQ
Last fiscal yearDec 2025
$11.91M-44.2% YoY
LTMMar 2026
$10.08M-60.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.8%——
1 year-44.2%——
3-year CAGR-22.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.91M USD
Year-over-year change
-44.2%
4-year CAGR
-13.1%

Stock-Based Compensation vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -60.8% is the 9th highest of 11, against a peer median of -30.4%.
  • Stock-based compensation amounts to 60.3% of revenue for PRLD, versus a peer median of 79.3%.
PRLD Competitors
Stock-Based Compensation for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M USD-32.8%+2.7%99.6%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M USD-60.8%-22.0%60.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$8.17M USD-33.3%-9.2%59.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M USD+42.2%—26.1%
IMRXImmuneering CorporationLTM Mar 2026$1.52M USD-69.5%——
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding PRLD) —-30.4%+4.4%79.3%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.